Kornimate/medical-research-clean huggingface dataset:
bioimpedance analysis guided volume expansion for the prevention of contrast induced-acute kidney injury

Conditions: X-ray Contrast Media Adverse Reaction

Summary: bioelectrical impedance analysis guided volume expansion for the prevention of contrast induced-acute kidney injury

compared bioelectrical impedance analysis guided hydration therapy versus standard hydration for the prevention of contrast induced-acute kidney injury

Eligibility criteria:
inclusion criteria: 1. age 18-90 yr 2. chronic kidney disease stage 3 \& 4 (egfr 15-60 ml/min/m2) 3. elective cardiac catheterization exclusion criteria: 1. contrast media administration in the past 14 days 2. congestive heart failure (nyha iii-iv, ascites , pleuropericardial effusion ,severe valvular heart disease 3. kidney transplant status or rrt 4. emergency cardiac catheterization 5. allergy to radiographic contrast media 6. unstable renal function (change in serum creatinine ≥ 0.5 mg/dl or 25% within 14 days prior to the study 7. not inform consent 8. left ventricular ejection fraction \< 40 % 9. liver cirrhosis child b or c 10. dosage of angiotensin-converting enzyme inhibitor /angiotensin ii receptor blocker changed in past 2 wk

Keywords: contrast induced acute kidney injury bioimpedance
evaluation of an alternative method of obtaining viral rna for the detection of sars-cov-2 virus using pcr

Conditions: COVID; SARS-CoV2; Corona Virus Infection

Summary: the current coronavirus disease pandemic has posed a problem and a challenge for health systems globally. in the framework of a pandemic, a diagnosis is a key tool in containing and monitoring disease outbreaks. in this pandemic, the qpcr technique has become vitally important in virus detection, due to its wide detection and quantification range, and the high levels of sensitivity and specificity it presents. the methodology for diagnosing coronavirus by qpcr requires the prior extraction of viral genetic material, which is carried out using commercial kits created for this purpose. currently, the high demand for supplies to carry out this technique has generated reagent shortage problems, including commercial kits for the extraction of viral genetic material. this research aims to evaluate a solution called aaa-safe and its method, developed to optimize the diagnostic process, eliminating and replacing the viral rna extraction stage. we hope that this alternative can be implemented in any molecular diagnostic laboratory, in order to speed up the delivery of a fast and safe diagnosis.

this analytical and non-interventional study will evaluate the performance of a new workflow for the detection of sars-cov-2 viral rna from samples of nasopharyngeal, oropharyngeal, buccal, nasal and saliva mucosa using as transport medium the propietary aaa-safe solution, in 150 volunteers in two different locations. the first sampling location will be held in a private clinic, where healthcare professionals will be enrolled. the second sampling location will be held at an essential services company, where samples will be taken by employees who voluntarily want to participate in the study. all volunteers will be informed of all aspects of this protocol and must sign an informed consent before there participation. all the information associated with the samples requested will be duly anonymized in order to protect the identity of the volunteers. the extracted samples will be processed and analyzed to obtain the detection limit of the diagnostic flow by implementing the developed solution and to establish the clinical performance in terms of sensitivity and specificity of the technique.

Eligibility criteria:
inclusion criteria: * 18 years and older * volunteer able to understand and sign the informed consent * healthcare professionals * essential services company workers exclusion criteria: * older than 75 years

Keywords: sars-cov-2 diagnostics rna extraction covid
aortic stenosis: determinants of progression, severity and left ventricular remodeling

Conditions: Aortic Valve Stenosis

Summary: aortic stenosis (as) is the most frequent valvulopathy in western countries. the prevalence of as is constantly increasing due to the aging of the population. although significant progress has been made in understanding the pathophysiological mechanisms underlying the onset and progression of as, there is no medical treatment to slow or prevent its progression. the only treatment available is aortic valve replacement (avr) performed by surgery or by catheterization (tavi). as is associated with an increase of post-load which leads the left ventricular myocardium to hypertrophy. associated with hypertrophy, myocardial fibrosis will gradually develop. despite interesting data, many unknowns persist and remain to be identified. the aim of the study is to evaluate prospectively the progression and impact of as in 500 patients using clinical, biological, echocardiographic and mri parameters performed annually.


Eligibility criteria:
inclusion criteria: * aortic stenosis (peak aortic valve velocity (vmax) ≥2.5m/s ) exclusion criteria: * rheumatismal or congenital aortic stenosis * aortic insufficiency (grade \>= 2/4) * associated valvulopathy (grade \>= 2/4) * angina, syncope, dyspnea nyha 3-4 * heart failure antecedent * myocardial infarction antecedent * severe renal failure * indication of aortic valve replacement (surgery or tavi) * cardiac surgery (aorta abdominal) antecedent * complex congenital cardiopathy

Keywords: aortic stenosis progression left ventricular remodeling
verteporfin photodynamic therapy administered in conjunction with ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (amd)

Conditions: Macular Degeneration; Choroidal Neovascularization

Summary: this study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration


Eligibility criteria:
inclusion criteria: * subjects of either gender age 50 years or older * subfoveal choriodal neovascularization (cnv) due to age-related macular degeneration (amd) exclusion criteria: * choriodal neovascularization due to causes other than amd * prior treatment for neovascular amd in the study eye other protocol-defined inclusion/exclusion criteria may apply

Keywords: age-related macular degeneration amd choroidal neovascularization verteporfin ranibizumab
evaluation of the effect of sitagliptin on gut microbiota in patients with newly diagnosed type 2 diabetes

Conditions: Type 2 Diabetes

Summary: the present study will recruit 9 newly diagnosed type 2 diabetic patient to receive sitagliptin 100mg daily for 12 weeks. the aim of this study was to investigate the composition of gut microbiota before and after the therapy of sitagliptin.

the present study will included 9 newly diagnosed type 2 diabetic patient to receive sitagliptin 100mg daily for 12 weeks. these patients will receive 75g oral glucose tolerance test and fasting plasma glucose levels, lipids levels, fasting insulin levels and 2 hour post-load plasma glucose levels will be measured. stool samples will be collected before the initiation of the use of sitagliptin. after 12 weeks, all patients will have fasting plasma glucose levels, lipids levels, fasting insulin levels tested. stool samples will be collected again.

Eligibility criteria:
inclusion criteria: * newly-diagnosed type 2 diabetic patients aged between 40-70 years exclusion criteria: * any chronic disease (other than diabetes) * alcohol consumption/smoking * pregnancy/breastfeeding * the use of antibiotics, pro-prebiotics within 3 months * history of intestinal surgery

Keywords: type 2 diabetes gut microbiota sitagliptin
gsk2018682 ftih in healthy volunteers

Conditions: Multiple Sclerosis

Summary: this protocol describes the first administration of gsk2018682 to humans. the study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of gsk2018682. the study will also provide preliminary evidence of the potential therapeutic dose-range by measuring the inhibitory effect of gsk2018682 on total lymphocyte counts.

this protocol describes the first administration of gsk2018682 to humans. the study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of gsk2018682. the study will also provide preliminary evidence of the potential therapeutic dose-range by measuring the inhibitory effect of gsk2018682 on total lymphocyte counts.

Eligibility criteria:
inclusion criteria: * healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. a subject with a clinical abnormality or laboratory parameters significantly outside the reference range for the population being studied may be included only if the investigator and the gsk medical monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. subjects with lymphocyte counts outside the normal range should always be excluded from enrollment * bmi within the range 19 - 28 kg/m2 (inclusive). exclusion criteria: * a positive pre-study hepatitis b surface antigen or positive hepatitis c antibody result within 3 months of screening * current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of gilbert's syndrome or asymptomatic gallstones). * a positive pre-study drug/alcohol screen. * a positive test for hiv antibody. * history of regular alcohol consumption * subjects with a history of, or examination suspicious for, skin cancer(s) including melanoma, basal cell or squamous cell carcinoma. * systolic blood pressure less than 95 mmhg or greater than 140 mmhg, or diastolic blood pressure less than or equal to 50 mmhg or greater than or equal to 95 mmhg. * symptomatic reduction in blood pressure after orthostatic challenge. * subjects with resting heart rate less than 45 beats per minute or greater than 90 beats per minute other criteria may apply as defined by the clinical protocol.

Keywords: gsk2018682 first time in human healthy volunteer
a combined transvenous and epicardial lead placement procedure for implantation of cardiac resynchronization devices: a feasibility study.

Conditions: Heart Failure With Intraventricular Conduction Delay

Summary: cardiac resynchronization therapy has become one of the cornerstones of the treatment of heart failure. however, a large proportion of patients still fails to this type of therapy. this may be due to a suboptimal position of the left ventricular pacing lead, which may be caused by unfavorable cardiac venous anatomy. implantation of the pacing lead using video assisted thoracic surgery is more flexible and evades the venous system altogether, resulting in a much more favorable position of the pacing lead, with better treatment results as e consequence.


Eligibility criteria:
inclusion criteria * nyha class ii-iii. * left ventricular ejection fraction ≤ 35%. * qrs-duration of ≥ 120 ms (nyha iii) or ≥ 130 ms (nyha ii) and left bundle branch block morphology. * no sidebranch of the coronary sinus near the posterolateral wall of the left ventricle and/or presence of a thebesian valve which reduces coronary sinus diameter 50% or more (corresponding to a decrease in cross sectional area of 75% or more). * on optimal medical therapy for heart failure, including beta-blockers, ace-inhibitors, at2-antagonists and aldosteron antagonists. * age ≥ 18 years. * signed informed consent. exclusion criteria a potential subject who meets any of the following criteria will be excluded from participation in this study: * coronary ischemia or a recent myocardial infarction (\< 6 months). * allready a crt-device implanted. * venous thrombosis without options to reach the right heart. * presence of any other condition than hf with a life expectancy of \< 1 year. * history of intrathoracic surgery. * presence or suspected presence of a noncompliant left lung. * participation in another intervention trial. * unable to understand dutch language. * pregnant women.
hpv self-sampling for cervical cancer screening among transgender men and transmasculine individuals

Conditions: Cervical Cancer Screening

Summary: the proposed study will examine the implementation of a human papillomavirus (hpv) self-sampling intervention for unscreened and under-screened transgender men and transmasculine individuals living in south florida. the study will enroll participants to receive this cervical cancer screening intervention in community venues. the purpose of this study is to pilot the self-sampler for feasibility and acceptability within this underserved population.


Eligibility criteria:
inclusion criteria: * self-identify as transgender male or as transmasculine * assigned female sex at birth * english speaking * ages 25-65 years * report not having had a pap smear in the last three years * if age 30 and over, report not having a pap smear/hpv co-test in the past 5 years exclusion criteria: * • those who report having had a hysterectomy * those who report having history of cervical cancer * adults unable to consent * those who are pregnant * prisoners
inspiratory muscle training prior to conventional and minimal invasive heart surgery

Conditions: Coronary Artery Bypass Graft Surgery; Valve Replacement; Post-Op Complications; Physiotherapy

Summary: the main objective of this study is to evaluate the effect of pre-operative inspiratory muscle training (imt) using an imt threshold device (philips), on early postoperative lung function recovery and on the occurrence of post-operative pulmonary complications (ppc) after major cardiothoracic surgery with and without sternotomy. as frailty can affect postoperative outcome, the relation between frailty, maximal inspiratory pressure (mip) and post-operative outcome is investigated additionally.

patients eligible for cardiac surgery are pre-operatively randomized to standard physiotherapy or daily inspiratory muscle training for a period of 2-3 weeks. one therapy session a week is supervised by a physiotherapist in the imt group. post-operative physiotherapy is standardized. pulmonary function and clinical status are evaluated pre-operatively, and during the early post-operative phase, approximately on the 3th and 6th post-operative day, or when necessary. the occurrence of postopercenterative pulmonary complications is determined using a validated scale, the melbourne group scale, based on clinical status, chest x-ray and blood tests. frailty is defined based on the fried criteria. two belgian hospitals are involved in this study: the university hospital brussels and the jessa hospital (hasselt), the latter mainly focussing on patients referred for minimal invasive heart surgery (minimally invasive-aortic valve replacement (mini-avr) and endoscopic - atraumatic coronary artery bypass (endo-acab).

Eligibility criteria:
inclusion criteria: * candidates for coronary artery bypass grafting or minimally invasive valve repair/replacement exclusion criteria: * not able to perform pre-operative standard pulmonary function tests * no understanding of dutch, french or english and/or no ability to understand verbal instructions regarding the inspiratory muscle training * patients who participate in another clinical trial * patients suffering from neuromuscular disorders, unstable angina, a history of non-traumatic pneumothorax, chronic obstructive pulmonary disease (copd) in exacerbation * patients in need for urgent surgery (within less than 2 weeks)

Keywords: post-operative complications inspiratory muscle training
impact of lifestyle changes on telomeric activity in patients with chronic pain

Conditions: Chronic Pain

Summary: the current project will use the complete health improvement program (chip) as an intervention for patients with chronic pain. chip is a nationally recognized program that encourages a diet of whole plant-based foods, moderate exercise, stress reduction, and social support. patients with chronic pain who enroll in chip classes will be monitored and compared to patients with chronic pain who are not enrolled in chip classes. it is hypothesized that patients who complete chip will have increased telomerase activity and longer relative telomere length at follow-up when compared to those who do not enroll in the program. chromosomes consist of dna that contains the genetic makeup of an individual; and telomeres are the caps on these chromosomes that protect them from damage. telomere shortening occurs normally with aging and once they are too short to replicate cellular death occurs. telomerase is a ribonucleic protein that counterbalances this shortening by extending the ends of chromosomes. research has shown that patients with chronic pain may have shorter telomeres relative to others of the same age. this study will investigate this association further.


Eligibility criteria:
inclusion criteria: * 40-70 years old * physician confirmed chronic pain diagnosis for at least 6 months exclusion criteria: * pregnancy * physical or mental condition that limits ability to provide consent or answer questionnaires

Keywords: chronic pain telomere telomerase life style
identification of biomarkers of attention deficit disorder with or without hyperactivity (adhd) by a metabolomic approach in children

Conditions: Adhd

Summary: attention-deficit with or without hyperactivity disorder (adhd) is a real health public concern. no easy-use diagnosis tool are available. metabolomic approaches has brought very usefull data in others neurological diseases like amyotrophic lateral sclerosis or autism spectrum disorder, as we had shown in previous studies. targeting on neurotransmitter pathways involving in adhd, metabolomic screening could help to enhance our diagnosis power to better help numerus of children. we propose to study the phenylalanine and the tyrosine pathways with a multimodal metabolomic approach, in easy-available biological fluid (blood and urine), in child or adolescent suspected of adhd. our objectives are: 1- to determine a specific metabolomic signature of adhd 2- to compare the diagnostic value of this metabolomic signature with the reference methodology for adhd diagnosis, as now practiced in our reference center for learning troubles.


Eligibility criteria:
inclusion criteria: * child or adolescent with symptoms of attention disorders and / or hyperactivity * aged from 6 to 15 years old exclusion criteria: * failure or refusal of all or part of the multidisciplinary evaluation (medical and / or neuropsychological assessments and / or biological assessments) * identification of an intercurrent condition likely to have an impact on metabolomic analyzes (acute infection, fever, etc.) * parents or legal guardians opposed to data processing

Keywords: adhd metabolomics child
effects of supplementation with ginseng and bcaa improved central fatigue and enhanced attention during exercise

Conditions: Exercise Addiction

Summary: the main purpose of the present study is to determine the effects of acute and short-term (14 days) ginseng combined with branch chained amino acids supplementation on endurance exercise performance and the ability of anti-fatigue. in addition, this study also measured the performance of continuous attention during recovery period to examine the effect of supplementation on central fatigue.

muscle fatigue was a common problem after exercise. when fatigue occured, body functions were affected and changed. changbai mountain ginseng had higher anti-fatigue substances than general commercial ginseng. and recent studies had showed that the supplementation of branched chain amino acids (bcaa), including leucine, isoleucine and valine, can increase attention and reduce fatigue. however, its effect on changbai mountain ginseng combined with bcaa was still unclear. subjects were allocated to gojinsen® drinks and placebo group (1:1 ratio) for 14 days, and then examined by maximal oxygen consumption, time to exhaustion, rating of perceived exertion (rpe), oxygen saturation (spo2) , blood lactate concentration, and continuous attention performance test (cpt ii). the gojinsen® group significant increased maximal oxygen consumption, time to exhaustion, and attention compared to placebo group. moreover, the gojinsen® group significant decreased lactate concentration and fatigue compared to placebo group. by this study, gojinsen® drinks did not showed absolute anti-fatigue effect but provided the objective evidence of fatigue-related measurement and the therapeutic potential for people suffering from exercise fatigue.

Eligibility criteria:
inclusion criteria: 1. healthy male and female adults aged 20-25 years old . 2. without heart, liver, kidney, endocrine or other major organic diseases). 3. had at least 3 months experience in performing exercise exclusion criteria: 1. bmi of the study subjects must be less than 25.
the effect of bovine colostrum/ egg supplementation in young malawian children

Conditions: Stunting; Environmental Enteric Dysfunction

Summary: the trial will consist of adding either a supplement of 4.3g egg powder + 5.7g bovine colostrum or a control flour along with a multiple micronutrient powder to the diets of healthy malawian children 9 months of age. this supplement provides additional essential amino acids, choline and immunoactive colostrum. children will be receive either the supplement or control for 12 weeks. children will have regular follow-up where anthropometry is measured. at enrollment and after 12 weeks, stool will be collected and a urinary lactulose permeability test conducted. children will be measured at enrollment and at weeks 2, 4, 8, 12, 20, 32 after enrollment.


Eligibility criteria:
inclusion criteria: * healthy children at 9-10 months of age exclusion criteria: * malnutrition * congenital abnormalities * chronic diseases such as heart disease, cerebral palsy, or hiv infection